• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

How Beneficial is One HPV Vaccine Dose vs the Complete Series?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Only approximately 50% of adolescents in the US. have completed the full HPV vaccine series
    • About 68% received at least one dose
    • Current trials are investigating the efficacy of a single dose regimen
  • Sonawane et al. (JAMA Network Open, 2019) assessed HPV infection prevalence and association of number of vaccine doses

METHODS:

  • Cross-sectional study
  • Data sources (2009 to 2016)
    • National Health and Nutritional Examination Survey (NHANES)
  • Participants
    • Women
    • 18 to 26 years
    • HPV vaccination and HPV test information available (i.e., no missing data)
    • Immunization history: Self-reported and collected by trained interviewers
    • Sexual behavior data: Self-reported
    • Cervicovaginal swab specimens: Obtained by patients and tested  
  • Study design and data analysis
    • Designed to examine the difference in the prevalence of HPV infection by number of doses received
    • Probability estimates for HPV types 6, 11, 16, and 18 generated based on number of vaccine doses and risk factors

RESULTS:

  • 1,620 women
    • Mean age: 22.2 years | 56.5% white
    • Unvaccinated: 1004 women
    • ≥1 dose of HPV: 616 women
      • 1 dose: 106 women
      • 2 doses: 126 women
      • 3 doses: 384 women
  • Infection with HPV type 6, 11, 16, or 18 was significantly less prevalent among women who received any number of HPV doses
    • Unvaccinated women: 12.5% (95% CI, 9.7% to 15.3%)
    • 1 dose: 2.4% (95% CI, 0% to 4.9%)
    • 2 doses: 5.1% (95% CI, 0.8% to 9.5%)
    • 3 doses: 3.1% (95% CI, 0.9% to 5.3%)
  • There was no significant difference in prevalence for
    • 1 dose vs 2 doses
    • 1 dose vs 3 doses
  • Predicted probability of infection with HPV 6, 11, 16, or 18 was higher in unvaccinated women
    • Unvaccinated women: 7.4% (95% CI, 7.1% to 7.7%)
    • 1 dose: 2.3% (95% CI, 1.9% to 2.8%)
    • 2 doses: 5.7 (95% CI, 5.1% to 6.2%)
    • 3 doses: 3.1% (95% CI, 2.9% to 3.4%)
  • Black women had a greater predicted probability (10.8%) of infection with HPV type 6, 11, 16, or 18 compared with white women (6.6%)
  • Predicted probability was also higher for women with more than 5 lifetime male sexual partners (11.6%) than women with 0 to 5 lifetime male partners (3.3%)

CONCLUSION:

  • Realistically, adolescents may not always complete the HPV vaccine series, for reasons including health insurance issues
  • The authors recognize limitations of the study including self-reporting
  • This study demonstrates that 1 dose of the HPV vaccine may result in similar protection compared to additional doses
  • The authors state

If ongoing trials confirm sufficient efficacy and sustained duration of protection from a single-dose regimen, vaccine initiation (as opposed to the series completion) will become a more achievable metric of population coverage



Learn More – Primary Sources:

Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

HPV Vaccines: Cochrane Reviews Looks at the Evidence with Multi-Year Follow-Up
The HPV Vaccine Leads to a Reduction in Cervical Precancers in Young Women in the U.S.
How has HPV Prevalence Changed Since Introduction of Vaccine?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site